The Major Peptide Classes Explained: A Taxonomy

A peptide is a short chain of amino acids — typically 2 to about 50 residues, molecular weight roughly 500–5,000 daltons — that acts in the body chiefly as a signaling molecule, binding receptors to switch biological processes on or off.1 But because "peptides" spans FDA-approved blockbusters and illegal research chemicals alike, the only useful way to reason about them is by their functional class — and then to grade the human evidence for each class's headline use.

This article is informational and editorial content for educational purposes only. It is not medical, legal, or regulatory advice, and it is not a sourcing or buying guide. Many peptides discussed here are not FDA-approved and are sold illegally as "research chemicals not for human use." Where doses or routes appear elsewhere in this library, they are reported strictly as seen in published literature. Consult a qualified, licensed clinician before making any health decision.

How should peptides actually be classified?

Peptides resist a single clean classification because the same molecule can be sorted by chemistry (cyclic vs. linear, lipidated, PEGylated), by origin (endogenous, synthetic analog, bioregulator), by route (injectable, intranasal, topical, oral), or by regulatory status (approved drug, compounding bulk substance, banned research chemical). This guide uses the functional/therapeutic axis — what the peptide is designed to do — because that is the axis a reader reasons along, and because it is the axis on which evidence accrues: trials are run for indications, and indications track function.

Two cross-cutting axes then apply to every class. The regulatory axis asks whether a peptide is an FDA-approved drug, a compounding bulk substance under review, or an unapproved research chemical, and whether it is on the WADA Prohibited List. The evidence-maturity axis assigns an A/B/C/D grade to the specific headline claim, not to the class as a whole. Grade A means human RCTs or meta-analyses (semaglutide for weight loss; teriparatide for fracture reduction). Grade B means human evidence below RCT level — cohort, observational, small, open-label, or single-arm (thymosin alpha-1 in sepsis subgroups; kisspeptin mechanism). Grade C means preclinical only — animal or in-vitro with no qualifying human efficacy data (BPC-157, TB-500, MOTS-c). Grade D means anecdote, mechanism-only, or marketing claim (most bioregulator longevity claims).

What are the eleven major peptide classes?

The table below is the map; each row is a class, and individual peptides within a class vary, so always check the specific molecule and its specific claim.

*Retatrutide and several dual/triple agonists are investigational, not yet FDA-approved for obesity as of mid-2026.

Which classes hold the Grade-A approved medicines?

The metabolic/incretin class is the flagship and the best-evidenced. Incretins are gut hormones that amplify insulin secretion; the drugs are engineered GLP-1, GIP, glucagon, and amylin analogs. In STEP 1 (n=1,961), once-weekly semaglutide produced roughly a 14.9% body-weight reduction versus 2.4% on placebo at 68 weeks.2 Tirzepatide, a GIP/GLP-1 dual agonist, reached up to 22.5% in SURMOUNT-1,3 and the investigational triple agonist retatrutide hit up to 24.2% in phase 2.4 The caveat is durability: STEP 1 participants regained about two-thirds of lost weight a year after stopping, confirming obesity as a chronic condition.5

The bone/calcium-endocrine class is small but also Grade A. Teriparatide (recombinant PTH 1-34) cut new vertebral fractures by roughly 65% in the landmark Fracture Prevention Trial;6 abaloparatide adds further fracture-reduction RCT evidence. In the growth-hormone axis, tesamorelin is the exception that proves the rule: an FDA-approved GHRH analog for HIV-associated visceral fat, with 15–18% reductions in visceral adipose tissue in phase 3 trials and a 2025 weekly-reconstitution approval.78 Everything else in that class — sermorelin, CJC-1295, ipamorelin, MK-677 — reliably raises GH and IGF-1 lab values but lacks outcome trials in healthy adults, leaving "GH optimization" at Grade C–D. Finally, the melanocortin agents earn Grade A in their approved niches: bremelanotide (Vyleesi) for hypoactive sexual desire disorder, from the RECONNECT phase 3 program,14 and afamelanotide (Scenesse) for erythropoietic protoporphyria.1516

Where does the evidence thin out — and why?

The consumer-peptide boom centers on the tissue-repair class, where the mechanism-versus-evidence gap is starkest. BPC-157 rests on three decades of reasonably consistent animal data, yet a 2025 systematic review that screened 544 articles found only one clinical study among 36 included,9 and a parallel review confirmed no completed human RCTs.10 TB-500 and pentadeca-arginate occupy the same Grade-C tier. The reason large trials are missing is commercial, not scientific: these are naturally derived, poorly patentable sequences, so no sponsor funds the tens of millions a definitive trial costs.10

The growth-factor class (IGF-1 variants, MGF, follistatin) is essentially Grade C for performance use; the best human data come from orphan gene-therapy contexts, such as a follistatin (AAV1-FS344) trial in Becker muscular dystrophy that improved walk distance in some patients — Grade B in a narrow disease setting, not evidence that follistatin builds muscle in healthy people.1112 The immune/thymic class shows what genuine Grade B looks like: thymosin alpha-1 is among the most-tested peptides in existence, and a 2025 meta-analysis suggests a 28-day sepsis mortality benefit, yet the largest single trial (TESTS) was negative overall.13

Further down, the cosmetic class yields modest topical benefits — GHK-Cu improved firmness and fine lines in a 2023 split-face trial, but less than retinoids.19 The nootropic class is an evidence patchwork dominated by under-replicated single-lab research; even a large cerebrolysin registry effort (ClinicalTrials.gov NCT02541227) has not produced convincing Cochrane-level benefit in acute stroke.27 The mitochondrial/longevity class spans a real orphan approval — elamipretide for Barth syndrome, despite missed primary endpoints in MMPOWER-3 and TAZPOWER202122 — down to MOTS-c (Grade C in humans)23 and epitalon-style bioregulators (Grade D). The antimicrobial/gut-barrier class is similar: LL-37 and KPV are preclinical,24 while larazotide is the cautionary tale — a positive phase 2 that failed at phase 3 when the required sample size proved impractical.2526

What do the two cross-cutting axes tell us in 2026?

Reading across the taxonomy, an evidence gradient emerges: the classes with the loudest marketing (tissue-repair, GH-optimization, longevity/bioregulator) cluster in Grades C–D, while the quietest, most clinical classes (incretin, bone) are Grade A. Regulatory status runs on a different track — it follows approval history, not function. More than 80 peptide drugs are FDA-approved across several classes,1 yet beginning September 2023 the FDA placed dozens of research peptides into its §503A Category 2 "may present significant safety risks" bucket; in 2026 it removed a tranche and scheduled Pharmacy Compounding Advisory Committee review for July 23–24, 2026.28293031 Compounding eligibility is not the same as FDA approval — it confers no validated indication, dose, or benefit–risk profile.

For athletes, the WADA Prohibited List bans entire classes at all times. Section S2 covers peptide hormones, growth factors, GH secretagogues, GHRH analogs, ghrelin mimetics, and IGF-1 and its analogs; repair peptides such as BPC-157 and TB-500 are prohibited too, with BPC-157 classed under the experimental-substance category S0.323334

Bottom line. "Peptides" is a category, not a verdict. Functional class organizes the field, but evidence grade decides what to believe — and the Grade-A classes are few and clinical while the most-marketed classes are the least-proven. Regulatory and evidence statuses are fast-moving; the July 23–24, 2026 PCAC meeting will materially change several peptides' compounding eligibility, so re-verify against the live FDA §503A/§503B bulks lists, Drugs@FDA, and the WADA Prohibited List before relying on any status.